KR20170026672A - Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 - Google Patents

Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 Download PDF

Info

Publication number
KR20170026672A
KR20170026672A KR1020177005930A KR20177005930A KR20170026672A KR 20170026672 A KR20170026672 A KR 20170026672A KR 1020177005930 A KR1020177005930 A KR 1020177005930A KR 20177005930 A KR20177005930 A KR 20177005930A KR 20170026672 A KR20170026672 A KR 20170026672A
Authority
KR
South Korea
Prior art keywords
composition
ornithine
liver
administration
bdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177005930A
Other languages
English (en)
Korean (ko)
Inventor
라지브 잘란
케이쓰 앤더슨
Original Assignee
유씨엘 비즈니스 피엘씨
오세라 테라퓨틱스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유씨엘 비즈니스 피엘씨, 오세라 테라퓨틱스, 아이엔씨. filed Critical 유씨엘 비즈니스 피엘씨
Publication of KR20170026672A publication Critical patent/KR20170026672A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020177005930A 2009-06-08 2010-06-08 Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 Ceased KR20170026672A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18515809P 2009-06-08 2009-06-08
US61/185,158 2009-06-08
US24074809P 2009-09-09 2009-09-09
US61/240,748 2009-09-09
US29637710P 2010-01-19 2010-01-19
US61/296,377 2010-01-19
PCT/US2010/037838 WO2010144498A2 (en) 2009-06-08 2010-06-08 Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127000293A Division KR101715008B1 (ko) 2009-06-08 2010-06-08 Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복

Publications (1)

Publication Number Publication Date
KR20170026672A true KR20170026672A (ko) 2017-03-08

Family

ID=43309444

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177005930A Ceased KR20170026672A (ko) 2009-06-08 2010-06-08 Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
KR1020127000293A Active KR101715008B1 (ko) 2009-06-08 2010-06-08 Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127000293A Active KR101715008B1 (ko) 2009-06-08 2010-06-08 Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복

Country Status (18)

Country Link
US (2) US20120157526A1 (enExample)
EP (3) EP2799067B1 (enExample)
JP (3) JP5749255B2 (enExample)
KR (2) KR20170026672A (enExample)
CN (2) CN104434894A (enExample)
AU (1) AU2010258888B2 (enExample)
BR (1) BRPI1012956A8 (enExample)
CA (2) CA2764587C (enExample)
DK (2) DK2440200T3 (enExample)
EA (2) EA025735B1 (enExample)
ES (2) ES2728948T3 (enExample)
IL (2) IL216811A (enExample)
MX (3) MX375116B (enExample)
NZ (2) NZ596916A (enExample)
PL (1) PL2440200T3 (enExample)
SG (1) SG176675A1 (enExample)
WO (1) WO2010144498A2 (enExample)
ZA (1) ZA201108988B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102237526B1 (ko) * 2019-11-07 2021-04-07 한국식품연구원 오르니틴 생성능이 우수한 락토바실러스 브레비스 wikim47를 이용한 마늘 발효 조성물

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
DK3263100T3 (da) 2009-04-03 2020-05-11 Ocera Therapeutics Inc L-ornithinphenylacetat og fremgangsmåder til fremstilling deraf
AU2010258888B2 (en) 2009-06-08 2014-08-07 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
MX360062B (es) 2010-10-06 2018-10-22 Ocera Therapeutics Inc Metodos de elaboracion de fenilacetato de l-ornitina.
CN102993037B (zh) * 2012-11-20 2015-03-04 南京工业大学 一种l-鸟氨酸苯乙酸盐的制备方法
CN106163528A (zh) 2014-01-29 2016-11-23 梅克芳识别有限公司 用于治疗肝脑病的甾族化合物
JP6673915B2 (ja) 2014-10-24 2020-03-25 マリンクロット ホスピタル プロダクツ アイピー リミテッド １型肝腎症候群患者の治療方法
CN107206021B (zh) * 2014-11-24 2021-09-03 Ucl商业有限公司 使用降氨疗法治疗与肝星状细胞激活相关的疾病
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
CN107708684A (zh) * 2015-04-20 2018-02-16 欧塞拉治疗有限公司 L‑鸟氨酸苯乙酸盐制剂
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
EP3337473A4 (en) * 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
WO2017053613A1 (en) * 2015-09-25 2017-03-30 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) * 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
MX389926B (es) 2015-11-13 2025-03-20 Ocera Therapeutics Inc Formulaciones de fenilacetato de l-ornitina
CN106109429A (zh) * 2016-07-26 2016-11-16 北京百奥药业有限责任公司 一种苯丁酸钠片剂及其制备方法
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11160826B1 (en) 2017-03-03 2021-11-02 United States Government As Represented By The Department Of Veterans Affairs Cholesterol lowering drugs for the treatment of hepatic encephalopathy
CN110740988A (zh) 2017-05-11 2020-01-31 欧塞拉治疗有限公司 制备l-鸟氨酸苯乙酸盐的方法
MA49906A (fr) 2017-08-14 2020-06-24 Axcella Health Inc Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
WO2019173148A1 (en) * 2018-03-05 2019-09-12 The United States Government As Represented By The United States Department Of Veterans Affairs Cholesterol lowering drugs for the treatment of hepatic encephalopathy
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
CN113966194A (zh) 2019-05-09 2022-01-21 欧塞拉治疗有限公司 评估和治疗肝性脑病的方法
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (enExample) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100161A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4857555A (en) 1985-09-12 1989-08-15 Brigham & Women's Hospital Method of treating catabolic dysfunction
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
JP2522034B2 (ja) 1988-12-27 1996-08-07 味の素株式会社 α−ケト酸・アミノ酸塩化合物及びその製造方法
DE4020980C1 (enExample) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5856481A (en) 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
ATE191615T1 (de) * 1995-02-23 2000-04-15 Novartis Nutrition Ag Aminosäurenzusammensetzungen und verwendung derselben klinischen nährung
AU2251897A (en) 1996-02-13 1997-09-02 Trustees Of The University Of Pennsylvania, The Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
EP1179347A4 (en) 1999-05-21 2002-06-26 Takeda Chemical Industries Ltd CONTROL SUBSTANCES FOR LIVER FUNCTION
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
CN1304723A (zh) 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
US20040192751A1 (en) 2001-03-15 2004-09-30 Takeshi Abe Amino acid composition for ameliorating liver failure
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
AU2003261825A1 (en) 2002-08-30 2004-03-19 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
JP4954867B2 (ja) 2004-05-06 2012-06-20 オステオロジックス エイ／エス 有機金属塩類を製造するための高収率で迅速な合成法
JP2008511611A (ja) 2004-08-30 2008-04-17 ルナメツド・インコーポレーテツド 治療用４−フェニル酪酸制御放出製剤
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
JPWO2007077995A1 (ja) 2006-01-05 2009-06-11 協和発酵バイオ株式会社 筋肉増量剤
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
CA2727088A1 (en) 2008-06-04 2009-12-10 Phenolics, Llc Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
DK3263100T3 (da) 2009-04-03 2020-05-11 Ocera Therapeutics Inc L-ornithinphenylacetat og fremgangsmåder til fremstilling deraf
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
AU2010258888B2 (en) 2009-06-08 2014-08-07 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
JP2011236160A (ja) 2010-05-11 2011-11-24 Shinshu Univ 非アルコール性肝疾患治療薬
MX360062B (es) 2010-10-06 2018-10-22 Ocera Therapeutics Inc Metodos de elaboracion de fenilacetato de l-ornitina.
WO2014081977A1 (en) 2012-11-21 2014-05-30 Bruce Scharschmidt Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
CN103705490B (zh) 2013-10-31 2016-08-17 蚌埠丰原医药科技发展有限公司 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺
CN107206021B (zh) 2014-11-24 2021-09-03 Ucl商业有限公司 使用降氨疗法治疗与肝星状细胞激活相关的疾病
CN107708684A (zh) 2015-04-20 2018-02-16 欧塞拉治疗有限公司 L‑鸟氨酸苯乙酸盐制剂
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
WO2017053613A1 (en) 2015-09-25 2017-03-30 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102237526B1 (ko) * 2019-11-07 2021-04-07 한국식품연구원 오르니틴 생성능이 우수한 락토바실러스 브레비스 wikim47를 이용한 마늘 발효 조성물

Also Published As

Publication number Publication date
MX375116B (es) 2025-03-06
BRPI1012956A2 (pt) 2017-06-06
EP2440200A4 (en) 2012-11-28
IL216811A (en) 2016-11-30
WO2010144498A2 (en) 2010-12-16
ES2728948T3 (es) 2019-10-29
JP2015163635A (ja) 2015-09-10
US20120157526A1 (en) 2012-06-21
JP6527497B2 (ja) 2019-06-05
EP2799067A1 (en) 2014-11-05
HK1203419A1 (en) 2015-10-30
CN102625699A (zh) 2012-08-01
IL216811A0 (en) 2012-02-29
EA201691430A1 (ru) 2017-02-28
MX2020009703A (es) 2020-10-07
EA201171396A1 (ru) 2012-10-30
MX2011013129A (es) 2012-03-14
CN102625699B (zh) 2014-08-20
JP5749255B2 (ja) 2015-07-15
DK2440200T3 (en) 2014-12-08
ZA201108988B (en) 2015-04-29
WO2010144498A9 (en) 2011-04-28
CA2997484C (en) 2020-05-12
CA2764587A1 (en) 2010-12-16
CA2997484A1 (en) 2010-12-16
EP2440200A2 (en) 2012-04-18
JP6250588B2 (ja) 2017-12-20
CN104434894A (zh) 2015-03-25
DK2799067T3 (da) 2019-06-03
IL248696B (en) 2020-05-31
ES2517340T3 (es) 2014-11-03
EP3517110A1 (en) 2019-07-31
EP2440200B8 (en) 2014-10-15
EP2440200B1 (en) 2014-08-27
NZ615091A (en) 2015-03-27
EP2799067B1 (en) 2019-04-03
CA2764587C (en) 2018-04-24
SG176675A1 (en) 2012-01-30
US20180161293A1 (en) 2018-06-14
HK1174264A1 (en) 2013-06-07
KR101715008B1 (ko) 2017-03-22
NZ596916A (en) 2013-09-27
AU2010258888A1 (en) 2012-02-02
US11266620B2 (en) 2022-03-08
BRPI1012956A8 (pt) 2021-11-03
AU2010258888B2 (en) 2014-08-07
JP2017066153A (ja) 2017-04-06
KR20120047891A (ko) 2012-05-14
PL2440200T3 (pl) 2015-08-31
JP2012529523A (ja) 2012-11-22
IL248696A0 (en) 2016-12-29
EA025735B1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
KR101715008B1 (ko) Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
CN105682653B (zh) 2，4-二硝基苯酚制剂和使用其的方法
AU2014250643A1 (en) Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
JP2018526403A5 (enExample)
JP2005528430A5 (enExample)
US20100158857A1 (en) Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
AU2020203126A1 (en) Pharmaceutical solution comprising dopamine for use in treating Parkinson's disease
HK40012204A (en) Treatment of inflammation using l-ornithine phenylacetate
HK1174264B (en) Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
HK1203419B (en) Treatment of brain inflammation using l-ornithine phenylacetate

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170302

Application number text: 1020127000293

Filing date: 20120105

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170328

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170523

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170906

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170523

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I